All news
Update14h ago · Nov 16, 2026, 12:42 CET

Hansa Biopharma up 51% since the CEO's purchase

Insider
Renée Aguiar Lucander
Role
Chief executive (VD)
Company
Hansa Biopharma (HNSA)
Transaction
Buy
Shares
47,000
Amount
SEK 1.5M
Price per share
SEK 31.98
Trade date
Sep 25, 2026
Filed
Sep 28, 2026, 3 days after the trade

Hansa Biopharma CEO Renée Aguiar Lucander bought 47,000 shares at SEK 31.98 on Sep 25, 2026. The stock traded at SEK 50.65 on November 16, 2026, 51.2% above the first close after the purchase.

The purchase totaled SEK 1.5M and was reported to Finansinspektionen on September 28, 2026, 3 days after the trade. No sales by Renée Aguiar Lucander in Hansa Biopharma have been reported since.

Before 2026-09-28, 4 holders had disclosed net short positions in Hansa Biopharma, together 2.64%; the largest, ActusRayPartners Limited, held 0.9%. The price of SEK 50.65 was recorded at 12:38 CET, delayed by 15 to 20 minutes.

HNSA +6.1% on the day, delayed quote Nov 16

Since purchase+51.2%SEK 33.50 → SEK 50.65 at 12:38 CET
Since filing+55.8%SEK 32.50 on Sep 29 → SEK 50.65
PurchaseSEK 1.5M47,000 shares on Sep 25, 2026
Days since purchase52No sales by this filer since

Price since the purchase

Daily close · SEK
+50%
0%
Sep 28 · first close 33.50 SEKNov 16 · 50.65 SEK
PurchaseFirst close above +50%

The filing

Pages in this item

Earlier news on Hansa Biopharma

  1. Market move5d agoHansa Biopharma up 11% after the CEO's September purchase